

Office of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

September 11, 2007 6:30 – 9:00 p.m.

1.	Executive Session Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreem (as provided by 33 VSA § 1998(f)(2))	6:30 - 7:00 nents
2.	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	7:00 - 7:05
3.	Medical Director Update	7:05 - 7:10
4.	 OVHA Pharmacy Administration Updates Tamper Resistant Prescription Pads Specialty Pharmacy Requests for Proposals SSDC Supplemental Rebate Procurement Update Vaccine Availability and the Vermont Department of Health Drug Use Patient Profiles 	7:10 - 7:25
5.	Follow-up Items from Previous Meeting Methadone	7:25 - 7:30
6.	Clinical Update: Drug Reviews (Public comment prior to Board action) Tekturna® (aliskiren) Coreg CR® (carvedilol phosphate extended release (ER)) Omnitrope® (somatropin [rDNA origin]) Soliris® Injection (eculizumab)	7:30 – 8:00
7.	Review of Newly-Developed/Revised Clinical Coverage Criteria (Public comment prior to Board action) Analgesics: Short Acting Narcotics and Stadol Nasal Spray (me categories) Anti-Anxiety: Anxiolytics Anti-Emetics: NK1 Antagonists Anti-Hyperkinesis and Anti-Narcolepsy (merging of categories)	

Anti-Infectives: Antibiotics: Oxazolidinones Chemical Dependency: Buprenorphine

Lipotropics: Miscellaneous/Combinations

Pulmonary: Systemic Glucocorticoids (Dose packs)

Glucocorticoids: Topical (Verdeso® (desonide 0.05% foam) (abbreviated review)

Management of Mental Health Medications (updated language)

	 Anti-Emetics: 5HT3 Antagonists Anti-Infectives: Antibiotics: Macrolides 	
	 Anti-Infectives: Antibiotics: Penicillins (Oral) 	
	 Anti-Infectives: Antibiotics: Quinolones 	
	 Anti-Infectives: Antioiotics: Quinoiones Anti-Infectives: Antivirals: Herpes 	
	*	
	 Anti-Migraine: Triptans 	
8.	Drug Classes – New	8:35 – 8:35
	 No new drug classes 	
9.	RetroDUR	8:35 - 8:45
	 Acetaminophen > 4 grams/day 	
	 Zetia[®] (ezetimibe) 	
	 Asthma Exacerbations/Asthma Management 	
	7 Istima Dadocioations/1 Istima Management	
10. New Drug Products Not Added to PDL		8:45 - 8:50
		0.50 0.55
11.	Updated New-to-Market Drug Monitoring Log	8:50 - 8:55
12	General Announcements	
14,		8:55 - 9:00
	FDA Safety Alerts	0:55 - 9:00
	 Thiazolidinedione Drug Class – Heart Failure/Ischemic Risks 	
13	. Adjourn	9:00
•	· · · · · · · · · · · · · · · · · · ·	ו00

Formatting Changes Only